Merck & Co., Inc. <MRK.N>: Barclays Raises Target Price to $150 From $140
MRK•Related News
Evercore Q2 FY26 net income falls 1.98% to $95.3 million; net revenues rise 19% to $990.2 million
EVR•
Ireland's Aon Q2 revenue up 2%
AON•
Boston Scientific Q2 results beat estimates on cardiovascular strength
BSX•
PSQ Holdings Q2 FY26 net loss narrows 33% to $5.6 million; revenue more than doubles 108% to $7.1 million
PSQH•
Ashland Inc <ASH.N>: BMO Raises Target Price to $75 From $68
ASH•